← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV21행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTPhase 2
Levetiracetam (Levetiracetam)
Beijing Pins Medical Co., Ltd·FRα
ORR 63%·t½ 1 h
Overview
Program
Levetiracetam
Overview
Company
Beijing Pins Medical Co., Ltd
Overview
Modality
CGT
Overview
Target
FRα
Overview
Indication
Neuroblastoma
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
MoA
Mechanism
binds to voltage-gated sodium channels (Nav) and N-methyl-d-aspartate receptor
PK/PD
Half-life
1 h
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
Epilepsy-Related Psychosis in Drug-Resistant Epilepsy With Nonconvulsive Status Epilepticus and Difficult Antipsychotic Titration: A Case Report.. Psychosis in epilepsy may be difficult to diagnose when altered consciousness, antiseizure medication changes, and psychotropic adverse effects coexist. We report a man in his late 50s with longstanding drug-resistant epilepsy and recurrent psychosis. H…
Clinical
Primary efficacy
ORR 63%
Clinical
ORR
63%
Clinical
Result source
ClinicalTrials.gov NCT02348216
Clinical
Data Tier / Score
A · 53
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 12일 (2일 전)